Vepotolizumab (POLIVY) launch date in China

In January 2023, the original drug Vipotuzumab (POLIVY) developed by Roche Pharmaceuticals has been approved by the National Medical Products Administration for marketing in China. The domestic name is Weipotuzumab for injection, and it is also sold under the trade name of Urova. It is an injectable preparation, but due to its short time on the market, it has not yet entered the scope of medical insurance.

Vepotuzumab is an anti-CD79b antibody that binds to monomethyl auristatin E and has shown significant clinical activity in follicular and diffuse large B-cell lymphoma (DLBCL). It is currently approved by the FDA in combination with bendamustine and rituximab (R-CHP) for patients with relapsed/refractory diffuse large B-cell lymphoma. Myelosuppression and peripheral neuropathy are the main toxicities of vepotuzumab , and the results of the phase 3 trial will confirm its role in the third-line treatment of DLBCL.

Vepotolizumab, which is marketed in China, is a strictly controlled drug and its purchase is relatively difficult. Specification The price per box of 30 mg may be around RMB 10,000, and the price of the Hong Kong version of 140 mg per box may be around RMB 60,000 (the price may fluctuate due to exchange rates). The price of the European version of vepotuzumab available overseas, Specifications per box of 140 mg, may be around RMB 90,000 (the price may fluctuate due to the exchange rate). The domestic original drug has basically the same ingredients as the foreign original drug and is expensive. There is currently no generic version of vepotuzumab on the market.